Citing Article List

The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of "“Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease”.

No.

Publication Date

Citing Article

1

2024

Ishfaq Ahmad Ahanger, Tanveer Ali Dar. Small molecule modulators of alpha-synuclein aggregation and toxicity: Pioneering an emerging arsenal against Parkinson’s disease, Ageing Research Reviews. 2024; 101: 102538102538.  https://doi.org/10.1016/j.arr.2024.102538

2

2025

Xin Liang, Balasz Gulyas, Mathangi Palanivel, Weng Kee Leong. A triosmium carbonyl cluster that inhibits α-synuclein aggregation and disassembles preformed aggregates, Chemical Communications. 2025;   https://doi.org/10.1039/D5CC01141H

3

2024

Anns Mahboob, Hasan Ali, AlJazi AlNaimi, Mahmoud Yousef, Mlaak Rob, Nawaf Ahmad Al-Muhannadi, Degiri Kalana Lasanga Senevirathne, Ali Chaari. Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy, Cells. 2024; 13: 1527.  https://doi.org/10.3390/cells13181527

4

2024

Emma Boström, Sagar S. Bachhav, Hao Xiong, Cindy Zadikoff, Qingbo Li, Eric Cohen, Ingeborg Dreher, Anna Torrång, Gunilla Osswald, Mikael Moge, Paulina Appelkvist, Johanna Fälting, Tomas Odergren. Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults, The Journal of Clinical Pharmacology. 2024; 64: 1432.  https://doi.org/10.1002/jcph.6103

5

2025

Ling-Xiao Yi, Eng King Tan, Zhi Dong Zhou. The α-Synuclein Seeding Amplification Assay for Parkinson’s Disease, International Journal of Molecular Sciences. 2025; 26: 389.  https://doi.org/10.3390/ijms26010389

6

2025

YuTing Liu, Minhua Yang, Kyle Fraser, Danielle Graham, Paul H. Weinreb, Andreas Weihofen, Warren D. Hirst, Jesse M. Cedarbaum, Blake Pepinsky. Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples, The Journal of Pharmacology and Experimental Therapeutics. 2025; 392: 100003100003.  https://doi.org/10.1124/jpet.124.002199

7

2025

Jean-Christophe Rochet, Wenzhu Qi, Deniz Kirik. Zero-length crosslinking: A breakthrough approach for evaluating target engagement in α-synuclein immunotherapy, The Journal of Pharmacology and Experimental Therapeutics. 2025; 392: 100036100036.  https://doi.org/10.1016/j.jpet.2024.100036

8

2025

Khuraijam Surjalal Singh, Rahul Verma, Nagendra Singh, Laishram Rajendrakumar Singh, Akshita Gupta. 2025; 211: 271.  https://doi.org/10.1016/bs.pmbts.2024.11.004